Get the Stockscreener App
12.61
5.30%
0.635
Cullinan Therapeutics Inc stock is traded at $12.61, with a volume of 406.86K.
It is up +5.30% in the last 24 hours and up +21.55% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$11.97
Open:
$11.97
24h Volume:
406.86K
Relative Volume:
0.40
Market Cap:
$745.54M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-3.416
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+15.96%
1M Performance:
+21.55%
6M Performance:
+54.10%
1Y Performance:
+22.38%
1-Day Range:
$11.53
$12.64
1-Week Range:
$10.78
$12.99
52-Week Range:
$5.68
$13.33
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
12.62 | 707.14M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.06 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.47 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.89 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.81 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.12 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $49,200.00 in Stock - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth? - Sahm
Cullinan Therapeutics (NASDAQ:CGEM) Cut to "Sell" at Wall Street Zen - MarketBeat
Stocks to watch: Cullinan Therapeutics sees RS rating jump to 91 - MSN
Insider Sell: Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics Inc (CGEM) - GuruFocus
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Gainers Report: Can Cullinan Therapeutics Inc outperform under higher oil prices2025 Support & Resistance & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength - Yahoo Finance
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Stocks To Watch: Cullinan Therapeutics Sees RS Rating Jump To 91 - Investor's Business Daily
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 10.6%Here's Why - MarketBeat
History Review: What is the Moat Score of Cullinan Therapeutics IncIPO Watch & Verified Momentum Stock Alerts - baoquankhu1.vn
Will Cullinan Therapeutics Inc benefit from AI trends2025 Market WrapUp & Risk Controlled Swing Alerts - baoquankhu1.vn
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 6.2%Here's What Happened - MarketBeat
Published on: 2026-01-11 22:17:06 - ulpravda.ru
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics provides corporate update, anticipated 2026 milestones - Yahoo Finance
Market Fear: Will Cullinan Therapeutics Inc. stock split again soonWeekly Stock Report & Real-Time Volume Triggers - ulpravda.ru
Will Cullinan Therapeutics Inc. stock split again soonProfit Target & Weekly Return Optimization Alerts - ulpravda.ru
How strong is Cullinan Therapeutics Inc. stock balance sheetQuarterly Trade Review & Reliable Breakout Stock Forecasts - ulpravda.ru
Today's Analyst Ratings Update: CGEM Price Target Raised to $27 - GuruFocus
Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook - TipRanks
Cullinan Therapeutics (CGEM) Outlines Key Developments for 2026 - GuruFocus
Cullinan Therapeutics plans data readouts for key autoimmune programs By Investing.com - Investing.com Australia
Cullinan Therapeutics plans data readouts for key autoimmune programs - Investing.com India
Cullinan Therapeutics Outlines 2026 Milestones for CLN-978 and CLN-049 Programs, NDA Submission for Zipalertinib - Quiver Quantitative
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - Chartmill
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 9.5%Here's Why - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (NQ:CGEM) - FinancialContent
Oncology Drugs Fast-Tracked by the FDA in December 2025 - Oncology News Central
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 3.9%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nadim Ahmed Sells 9,922 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Assenagon Asset Management S.A. Has $1.05 Million Stake in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $13,463.45 in Stock - MarketBeat
Cullinan Therapeutics CSO Sells Shares - TradingView — Track All Markets
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $28,023.66 in Stock - Defense World
Cullinan Therapeutics (CGEM) Price Target Increased by 19.75% to 32.84 - Nasdaq
Will Cullinan Therapeutics Inc. stock deliver shareholder value2025 Price Targets & Weekly High Potential Stock Alerts - ulpravda.ru
Cullinan Therapeutics price target raised to $34 from $25 at Wedbush - MSN
Cullinan Therapeutics Earnings Notes - Trefis
Cullinan Therapeutics shows rising price performance with jump to 93 RS rating - MSN
Is Cullinan Therapeutics Inc. stock a contrarian buy2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - Улправда
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.26%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):